The National Cancer Institute (NCI) is seeking a candidate with a Bachelors, Masters, and/or Doctoral degree in the field of toxicology, or an appropriate discipline of the biological, medical, or veterinary sciences that includes at least 30 semester hours in chemistry, biochemistry, or physiology, and 12 semester hours in toxicology. The candidate will be responsible for designing segments of toxicology projects and/or studies to support the development of new drugs or biologics; coordinating and evaluating tasks associated with toxicology studies; presenting scientific findings to internal and external stakeholders; and serving as a technical consultant in the area of toxicology.
Applicants must be U.S. citizens. Grade and salary are dependent upon experience. Knowledge of the principles, theories, and methods of toxicology research activities as relates to new drug development is required.
How to Apply:
Interested candidates should send a letter of application, curriculum vitae, and full contact information for three references to: Elizabeth R. Glaze, Ph.D., D.A.B.T., Chief, TPB, DTP, DCTD, at: email@example.com.
The NIH and NCI are dedicated to building a diverse community in its training and employment programs and encourages the application and nomination of qualified women, minorities, and individuals with disabilities.
This position is located in the Toxicology and Pharmacology Branch (TPB), Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI), The National Cancer Institute is responsible for planning, directing and evaluating a collaborative, extramural, contract-supported program in anticancer drug (small molecule) and anticancer biological (large molecule, i.e., vaccine or antibody) development. DCTD and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. DCTD is expected to provide the preclinical pharmacology and toxicology expertise needed to generate data used in formulating recommendations for clinical dosing, dose escalation schemes and treatment schedules for clinical trials. DCTD provides drug development expertise to the NCI through the NCI Experimental Therapeutics (NExT) program. NExT is a joint therapeutics development program in which extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This program combines the strengths of DCTD's extensive expertise in anticancer drug develop...ment with CCR's dynamic in-house research and its location within state-of-the-art facilities at the NIH Clinical Center.